Dr Reddy’s Laboratories failed to cheer the market despite June quarter net profit doubling. Analysts see concern over the US business and pressure on operating performance as key drags. These concerns have prompted traders to build bearish bets on the stock. Chandan Taparia, derivative analyst at Motilal Oswal, said the weakness could continue and the stock could drift down to Rs 3,950.
Mcap of top-10 most valued firms slumps Rs 4.95 lakh cr; TCS, Reliance hardest hit
The combined market valuation of all the top-10 most valued firms plunged Rs 4,95,061 crore last week, in line with a bearish trend in equities,
December 22, 2024